Promotion of an unlicensed medicine by Allergy 皇冠体育apprapeutics
Published 14 December 2021
漏 Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, 皇冠体育app National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/publications/advertising-investigations-october-2021/promotion-of-an-unlicensed-medicine-by-allergy-therapeutics
ALK complained to the MHRA about materials disseminated by Allergy 皇冠体育apprapeutics about Venomil, an unlicensed medicine available as a 鈥榮pecial鈥�. 皇冠体育app complainant alleged that proactive communication with healthcare professionals and the distribution of material about Venomil constituted the promotion of an unlicensed medicine.
Following review of a letter supplied by Allergy 皇冠体育apprapeutics and their assurance that other materials are only supplied to healthcare professionals in response to an unsolicited request, MHRA did not uphold the complaint. Advice was provided on ensuring that no product claims were included in any future materials to be distributed proactively or in response to enquiries.